In vitro activity of tigecycline against multidrug-resistant Acinetobacter baumannii and selection of tigecycline-amikacin synergy

Antimicrobial Agents and Chemotherapy

Volumn 52, Issue 8, 2008, Pages 2940-2942

  Moland, Ellen S ^a   Craft, David W ^b,c   Hong, Seong Geun ^a   Kim, Soo Young ^a   Hachmeister, Lucas ^a   Sayed, Shimon D ^a   Thomson, Kenneth S ^a  

^a CREIGHTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b WALTER REED ARMY MEDICAL CENTER   (United States)

^c First Area Medical Laboratory   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; CEFTAZIDIME; GENTAMICIN; IMIPENEM; LEVOFLOXACIN; MINOCYCLINE; PIPERACILLIN PLUS TAZOBACTAM; POLYMYXIN B; SULTAMICILLIN; TIGECYCLINE;

ACINETOBACTER BAUMANNII; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIUM ISOLATE; CONTROLLED STUDY; MICROBIAL ACTIVITY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL;

ACINETOBACTER BAUMANNII; AMIKACIN; DRUG RESISTANCE, MULTIPLE, BACTERIAL; DRUG SYNERGISM; MICROBIAL SENSITIVITY TESTS; MINOCYCLINE;

EID: 48749119558     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.01581-07     Document Type: Article

References (16)

1. Arroyo, L. A., A. Garcia-Curiel, M. E. Pachon-Ibanez, A. C. Llanos, M. Ruiz, J. Pachon, and J. Aznar. 2005. Reliability of the E-test method for detection of colistin resistance in clinical isolates of Acinetobacter baumannii. J. Clin. Microbiol. 43:903-905.
2. Bonomo, R. A., and D. Szabo. 2006. Mechanisms of multidrug resistance in Acinetobacter species and Pseudomonas aeruginosa. Clin. Infect. Dis. 43(Suppl. 2):S49-S56.
3. Brown, S., and S. Amyes. 2006. OXA (bcta)-laclamases in Acinetobacter: the story so far. J. Antimicrob. Chemother. 57:1-3.
4. Gaynes, R., and J. R. Edwards. 2005. Overview of nosocomial infections caused by gram-negative bacilli. Clin. Infect. Dis. 41:848-854.
5. Henwood, C. J., T. Gatward, M. Warner, D. James, M. W. Stockdale, R. P. Spence, K. J. Towner, D. M. Livermore, and N. Woodford. 2002. Antibiotic resistance among clinical isolates of Acinetobacter in the UK, and in vitro evaluation of tigecycline (GAR-936). J. Antimicrob. Chemother. 49:479-487.
6. Lister, P. D., and D. J. Wolter. 2005. Levofloxacin-imipenem combination prevents the emergence of resistance among clinical isolates of Pseudomonas aeruginosa. Clin. Infect. Dis. 40(Suppl. 2):S105-S114.
7. Lister, P. D., D. J. Wolter, P. A. Wickman, and M. D. Reisbig. 2006. Levofloxacin/imipenem prevents the emergence of high-level resistance among Pseudomonas aeruginosa strains already lacking susceptibility to one or both drugs. J. Antimicrob. Chemother. 57:999-1003.
8. Manikal, V. M., D. Landman, G. Saurina, E. Oydna, H. Lal, and J. Quale. 2000. Endemic carbapenem-resistant Acinetobacter species in Brooklyn, New York: citywide prevalence, interinstitutional spread, and relation to antibiotic usage. Clin. Infect. Dis. 31:101-106.
9. Milatovic, D., F. J. Schmitz, J. Verhoef, and A. C. Fluit. 2003. Activities of the glycylcycline tigecycline (GAR-936) against 1,924 recent European clinical bacterial isolates. Antimicrob. Agents Chemother. 47:400-404.
10. Navon-Venezia, S., A. Leavitt, and Y. Carmeli. 2007. High tigecycline resistance in multidrug-resistant Acinetobacter baumannii. J. Antimicrob. Chemother. 59:772-774.
11. Peleg, A. Y., B. A. Potoski, R. Rea, J. Adams, J. Sethi, B. Capitano, S. Husain, E. J. Kwak, S. V. Bhat, and D. L. Paterson. 2007. Acinetobacter baumannii bloodstream infection while receiving tigecycline: a cautionary report. J. Antimicrob. Chemother. 59:128-131.
12. Perez, F., A. M. Hujer, K. M. Hujer, B. K. Decker, P. N. Rather, and R. A. Bonomo. 2007. Global challenge of multidrug-resistant Acinetobacter baumannii. Antimicrob. Agents Chemother. 51:3471-3484.
13. Quale, J., S. Bratu, D. Landman, and R. Heddurshetti. 2003. Molecular epidemiology and mechanisms of carbapenem resistance in Acinetobacter baumannii endemic in New York City. Clin. Infect. Dis. 37:214-220.
14. Sader, H. S., and R. N. Jones. 2005. Comprehensive in vitro evaluation of cefepime combined with aztreonam or ampicillin/sulbactam against multidrug resistant Pseudomonas aeruginosa and Acinetobacter spp. Int. J. Antimicrob Agents 25:380-384.
15. Swenson, J. M., G. E. Killgore, and F. C. Tenover. 2004. Antimicrobial susceptibility testing of Acinetobacter spp. by NCCLS broth microdilution and disk diffusion methods. J. Clin. Microbiol. 42:5102-5108.
16. Yoon, J., C. Urban, C. Terzian, N. Mariano, and J. J. Rahal. 2004. In vitro double and triple synergistic activities of polymyxin B, imipenem, and rifampin against multidrug-resistant Acinetobacter baumannii. Antimicrob. Agents Chemother. 48:753-757.